Can tailored nanoceria act as a prebiotic? Report on improved lipid profile and gut microbiota in obese mice
Microbiome modulation is a pillar intervention to treat metabolic syndrome, prestages, and cascade of related pathologies such as atherosclerosis, among others. Lactobacillus and Bifidobacterium probiotic strains demonstrate efficacy to reduce obesity, dyslipidemia, and improve metabolic health. Novel prebiotic substances composed with known probiotics may strongly synergize health benefits to the host. The aim of this study was to evaluate beneficial effects of Lactobacillus and Bifidobacterium strains (probiotics) if composed with nanoceria (potential prebiotic) to reduce cholesterol levels and restore gut microbiota in obese mice.
Materials and Methods
Two lines of mice were used in the study: BALB/c mice (6–8 weeks, 18–24 g) and CBA mice (11–12 months, 20–26 g); experimental animals were fed by fat-enriched diet 3 weeks before the evaluation. Animals were divided into groups to test probiotic strains and nanoceria. All groups received probiotic strains orally and cerium dioxide orally or intravenously in various composition. A group of untreated animals was used as a control. Cholesterol level and gut microbiota of mice were studied.
Cerium dioxide nanoparticles, probiotic strain L. casei ІМV В-7280, and composition B. animalis VKB/B. animalis VKL applied separately and in different combinations all reduced at different levels free and bound cholesterol in blood serum of mice fed by fat-enriched diet. The combination of 0.01 M nanoceria and probiotic strain L. casei ІМV В-7280 resulted in the fastest cholesterol level decrease in both young and mature animals. Oral administration of CeO2 applied alone reduced the number of microscopic fungi in the gut of mice and Gram-positive cocci (staphylococci and/or streptococci). Application of L. casei IMV B-7280 as a probiotic strain increased most significantly the number of lactobacilli and bifidobacteria in the gut of mice. The most significant normalization of gut microbiota was observed after oral administration of alternatively either L. casei IMV B-7280 + 0.1 M CeO2 or L. casei IMV B-7280 + 0.01 M CeO2.
Dietary application of nanoceria combined with probiotic strains L. casei IMV B-7280, B. animalis VKB, and B. animals VKL has significantly reduced both free and bound cholesterol levels in serum. Simultaneous administration of probiotics and cerium nanoparticles as a prebiotic, in various combinations, significantly enhanced positive individual effects of them on the gut microbiota spectrum. The presented results provide novel insights into mechanisms behind nutritional supplements and open new perspectives for application of probiotics combined with substances demonstrating prebiotic qualities benefiting, therefore, the host health. Follow-up translational measures are discussed to bring new knowledge from lab to the patient. If validated in a large-scale clinical study, this approach might be instrumental for primary and secondary prevention in obese individual and patients diagnosed with diabetes. To this end, individualized prediction and treatments tailored to the person are strongly recommended to benefit the health condition of affected individuals.
KeywordsPredictive preventive personalized medicine Nanoceria Nanoparticles Prebiotic Probiotic Obesity Metabolic syndrome Atherosclerosis Animal model Improved metabolism In vivo Microbiome Gut microbiota Lactobacillus Bifidobacterium Cholesterol Phenotype
The study was conducted with the support of the State Agency on Science, Innovations and Informatisation of Ukraine.
Rostyslav Bubnov created concepts and designed the study, participated in experiments, performed ultrasound investigations and analytical procedures, and drafted discussion and outlook. Lidiia Babenko and Liudmyla Lazarenko performed experiments on animals, corresponding analysis, and statistical evaluation, and created the first draft of manuscript. Maryna Kryvtsova, Nadiya Zholobak, and Oleksandr Shcherbakov participated in analytical approaches. Olga Golubnitschaja contributed to main concepts of the study, data interpretation and multidisciplinary aspects, and strengthened the expertise related to predictive, preventive, and personalized medicine. Mykola Spivak supervised the project and contributed to the data interpretation.
All authors read and approved the final manuscript.
Compliance with ethical standards
The authors declare that they have no competing interests.
Ethics approval and consent to participate
This study has been approved by the ethics committee of institutional review board and Special Academic Council on Doctoral Thesis of D.K. Zabolotny Institute of Microbiology and Virology of the National Academy of Sciences of Ukraine (protocol N 7 issued 03.07.2018).
No human subjects were included into the study.
- 2.World Health Organization (2018). Obesity and overweight. Fact sheet. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. (Accessed 25.10.2019).
- 3.World Health Organization (2017). Cardiovascular diseases (CVDs). Fact sheet. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds). (Accessed 25.10.2019).
- 4.Golubnitschaja O, Costigliola V, EPMA. General report & recommendations in predictive, preventive and personalised medicine 2012: white paper of the European Association for Predictive, Preventive and Personalised Medicine. EPMA J. 2012;3(1):14. https://doi.org/10.1186/1878-5085-3-14.
- 6.Golubnitschaja O, Costigliola V, EPMA. EPMA summit 2014 under the auspices of the presidency of Italy in the EU: professional statements. EPMA J. 2015;6(1):4. doi: 10.1186/s13167-015-0026-2.Google Scholar
- 8.Ndumele CE, Nasir K, Conceiçao RD, Carvalho JAM, Blumenthal RS, Santos RD. Hepatic steatosis, obesity, and the metabolic syndrome are independently and additively associated with increased systemic inflammation. Arterioscler Thromb Vasc Biol. 2011;31(8):1927–32. https://doi.org/10.1161/ATVBAHA.111.228262.CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Srikanthan K, Feyh A, Visweshwar H, Shapiro JI, Sodhi K. Systematic review of metabolic syndrome biomarkers: a panel for early detection, management, and risk stratification in the West Virginian Population. Int J Med Sci. 2016;13(1):25–38. https://doi.org/10.7150/ijms.13800.CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Bogiatzi C, Gloor G, Allen-Vercoe E, Reid G, Wong RG, Urquhart BL, et al. Metabolic products of the intestinal microbiome and extremes of atherosclerosis. Atherosclerosis. 2018;273:91–7. https://doi.org/10.1016/j.atherosclerosis.2018.04.015.CrossRefPubMedGoogle Scholar
- 13.Reijnders D, Goossens GH, Hermes GD, Neis EP, van der Beek CM, Most J, et al. Effects of gut microbiota manipulation by antibiotics on host metabolism in obese humans: a randomized double-blind placebo-controlled trial. Cell Metab. 2016;24(1):63–74. https://doi.org/10.1016/j.cmet.2016.06.016.CrossRefPubMedGoogle Scholar
- 16.Bubnov RV, Babenko LP, Lazarenko LM, Mokrozub VV, Demchenko OA, Nechypurenko OV, et al. Comparative study of probiotic effects of Lactobacillus and Bifidobacteria strains on holesterol levels, liver morphology and the gut microbiota ino bese mice. EPMA J. 2017;8(4):357–76. https://doi.org/10.1007/s13167-017-0117-3.CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Babenko LP, Sokolviak OY, Мokrozub VV, Nechypurenko OO, Demchenko OM, Bubnov RV, et al. Lactobacillus and Bifidobacterium probiotic strains reduce cholesterol levels and affect the gut microbiota in obese mice. United European Gastroenterol J. 2016;4(5S):A374–5. https://doi.org/10.1177/2050640616663689.CrossRefGoogle Scholar
- 26.Kristensen NB, Bryrup T, Allin KH, Nielsen T, Hansen TH, Pedersen O. Alterations in fecal microbiota composition by probiotic supplementation in healthy adults: a systematic review of randomized controlled trials. Genome Med. 2016;8(1):52. https://doi.org/10.1186/s13073-016-0300-5.CrossRefPubMedPubMedCentralGoogle Scholar
- 35.Bhaskaran K, Dos-Santos-Silva I, Leon DA, Douglas IJ, Smeeth L. Association of BMI with overall and cause-specific mortality: a population-based cohort study of 3·6 million adults in the UK. Lancet Diabetes Endocrinol. 2018;6(12):944–53. https://doi.org/10.1016/S2213-8587(18)30288-2.CrossRefPubMedPubMedCentralGoogle Scholar
- 36.Golubnitschaja O. Flammer syndrome in the global context – the “U-Shape” of health risks. Flammer syndrome – from phenotype to associated pathologies, prediction, prevention and personalisation. Springer 2019, ISBN 978-3-030-13549-2 ISBN 978-3-030-13550-8 (eBook), https://doi.org/10.1007/978-3-030-13550-8.Google Scholar
- 37.Bubnov R and Golubnitschaja O. Flammer syndrome, disordered eating and microbiome: interrlations, complexity of risks and individual outcomes. In book. Flammer syndrome – from phenotype to associated pathologies, prediction, prevention and personalisation. Springer 2019, ISBN 978-3-030-13549-2 ISBN 978-3-030-13550-8 (eBook), https://doi.org/10.1007/978-3-030-13550-8 Google Scholar
- 39.Gibson GR, Hutkins R, Sanders ME, Prescott SL, Reimer RA, Salminen SJ, et al. Expert consensus document: the International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol. 2017 Aug;14(8):491–502. https://doi.org/10.1038/nrgastro.2017.75.CrossRefPubMedGoogle Scholar
- 42.Konopelniuk VV, Goloborodko II, Ishchuk TV, Synelnyk TB, Ostapchenko LI, Spivak MY, et al. Efficacy of Fenugreek-based bionanocomposite on renal dysfunction and endogenous intoxication in high-calorie diet-induced obesity rat model—comparative study. EPMA J. 2017;8:377–90. https://doi.org/10.1007/s13167-017-0098-2.CrossRefPubMedPubMedCentralGoogle Scholar
- 44.Nido SA, Shituleni SA, Mengistu BM, Liu Y, Khan AZ, Gan F, et al. Effects of selenium-enriched probiotics on lipid metabolism, antioxidative status, histopathological lesions, and related gene expression in mice fed a high-fat diet. Biol Trace Elem Res. 2016;171(2):399–409. https://doi.org/10.1007/s12011-015-0552-8.CrossRefPubMedGoogle Scholar
- 47.Beregova TV, Neporada KS, Skrypnyk M, Falalyeyeva TM, Zholobak NM, Shcherbakov OB, et al. Efficacy of nanoceria for periodontal tissues alteration in glutamate-induced obese rats-multidisciplinary considerations for personalized dentistry and prevention. EPMA J. 2017;8(1):43–9. https://doi.org/10.1007/s13167-017-0085-7.CrossRefPubMedPubMedCentralGoogle Scholar
- 48.Zholobak NM, Ivanov VK, Shcherbakov AB, Shaporev AS, Polezhaeva OS, Baranchikov AY, et al. UV-shielding property, photocatalytic activity and photocytotoxicity of ceria colloid solutions. J Photochem Photobiol B. 2011;102(1):32–8. https://doi.org/10.1016/j.jphotobiol.2010.09.002.CrossRefPubMedGoogle Scholar
- 50.Kobyliak N, Virchenko O, Falalyeyeva T, Kondro M, Beregova T, Bodnar P, et al. Cerium dioxide nanoparticles possess anti-inflammatory properties in the conditions of the obesity-associated NAFLD in rats. Biomed Pharmacother. 2017;90:608–14. https://doi.org/10.1016/j.biopha.2017.03.099.CrossRefPubMedGoogle Scholar
- 51.Babenko LP, Zholobak NM, Shcherbakov AB, Woychuk SI, Lazarenko LM. Spivak MYa: Antimicrobial action of the ceria colloid solution on opportunistic microorganisms in vitro. Mikrobiol Zh. 2012;74(3):54–62.Google Scholar
- 62.Behrouz V, Jazayeri S, Aryaeian N, Zahedi MJ, Hosseini F. Effects of probiotic and prebiotic supplementation on leptin, adiponectin, and glycemic parameters in non-alcoholic fatty liver disease: a randomized clinical trial. Middle East J Dig Dis. 2017;9(3):150–7. https://doi.org/10.15171/mejdd.2017.66.CrossRefPubMedPubMedCentralGoogle Scholar
- 68.Lazarenko L, Melnikova O, Babenko L, Bubnov R, Beregova T, Falalyeyeva T, et al. Lactobacillus and Bifidobacteria probiotic strains improve glycemic and inflammation profiles in obesity model in mice. Preprints. 2018. https://doi.org/10.20944/preprints201808.0169.v1.
- 72.Oró D, Yudina T, Fernández-Varo G, Casals E, Reichenbach V, Casals G, et al. Cerium oxide nanoparticles reduce steatosis, portal hypertension and display anti-inflammatory properties in rats with liver fibrosis. J Hepatol. 2016;64(3):691–8. https://doi.org/10.1016/j.jhep.2015.10.020.CrossRefPubMedGoogle Scholar
- 73.Parra-Robert M, Casals E, Massana N, Zeng M, Perramón M, Fernández-Varo G, Morales-Ruiz M, Puntes V, Jiménez W, Casals G. Beyond the scavenging of reactive oxygen species (ROS): direct effect of cerium oxide nanoparticles in reducing fatty acids content in an in vitro model of hepatocellular steatosis. Biomolecules. 2019;9(9). https://doi.org/10.3390/biom9090425.CrossRefGoogle Scholar
- 81.Zholobak NM, Ivanov VK, Shcherbakov AB. Interaction of nanoceria with microorganisms. In: Grumezescu AM, editor. Nanobiomaterials in Antimicrobial Therapy. Bucharest: Elsevier Inc.; 2016. p. 419–50. https://doi.org/10.1016/B978-0-323-42864-4.00012-9.CrossRefGoogle Scholar
- 91.Parra-Robert M, Casals E, Massana N, Zeng M, Perramón M, Fernández-Varo G, Morales-Ruiz M, Puntes V, Jiménez W, Casals G. Beyond the Scavenging of Reactive Oxygen Species (ROS): Direct Effect of Cerium Oxide Nanoparticles in Reducing Fatty Acids Content in an In Vitro Model of Hepatocellular Steatosis. Biomolecules. 2019;9(9). pii: E425. https://doi.org/10.3390/biom9090425.CrossRefGoogle Scholar
- 92.Lye HS, Khoo BY, Karim AA, Rusul G, Liong MT. Ultrasound enhanced growth and cholesterol removal of Lactobacillus fermentum FTDC 1311 in the parent cells but not the subsequent passages. Ultrason Sonochem. 2012;19(4):901–8. https://doi.org/10.1016/j.ultsonch.2011.12.018.].CrossRefPubMedGoogle Scholar
- 95.Bubnov RV, Spivak MY. Sonoporation delivery of inorganic nanoparticles into bacterial cell of probiotic strains using diagnostic ultrasound machine. Ultrasound Med Biol. 2019;45:S83. https://doi.org/10.1016/j.ultrasmedbio.2019.07.282.CrossRefGoogle Scholar
- 96.Мokrozub VV, Lazarenko LM, Sichel LM, Babenko LP, Lytvyn PM, Demchenko OM, Melnichenko YO, Boyko NV, Biavati B, DiGioia D, Bubnov RV, Spivak MY. The role of beneficial bacteria wall elasticity in regulating innate immune response. EPMA J. 2015;6(1):13. https://doi.org/10.1186/s13167-015-0035-1.
- 97.Bubnov R, Babenko L, Lazarenko L, et al. Lactobacillus and Bifidobacterium strains and compositions with nanoceria reduce cholesterol levels in an obesity mouse model. EFSA congress 2018 in Parma, Italy. EFSA Journal 09/2018; 16(Suppl. 1):157. https://www.efsa.europa.eu/sites/default/files/event/180918-conference/conference18-EFSA_Journal_abstracts.pdf. (Accessed 25.10.2019).
- 98.Bubnov R, Spivak M. Towards Individualized Use of Probiotics and Prebiotics for Metabolic Syndrome and Associated Diseases Treatment: Does Pathophysiology-Based Approach Work and Can Anticipated Evidence Be Completed?. Preprints 2018, 2018090185. https://doi.org/10.20944/preprints201809.0185.v1.